Anti-IL-23a Antibody (Risankizumab)
Catalog No.
F1241
Anti-IL-23a Antibody (Risankizumab)
Featured Products
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that targets the IL-23 p19 subunit (Kd <10 pM) and inhibits human IL-23-induced IL-17 production in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to study immune and inflammatory diseases such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145.92 kDa
Dry ice
1612838-76-2
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SKYRIZI, BI 655066, ABBV-066
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9NPF7
Human, Cynomolgus
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human IL 23P40 His at 2 ug/mL can bind Anti-IL-23a Antibody (Risankizumab)
IL-23a
Please avoid freeze-thaw cycles.